MCID: SPP010
MIFTS: 54

Suppressor of Tumorigenicity 3

Categories: Cancer diseases

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 57 73
Cervical Carcinoma 57 55
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 57
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 57
Tumor-Suppressor Gene, Hela Cell Type; Tshl 57
Tumor-Suppressor Gene, Hela Cell Type 57
Cervix Carcinoma 73
Tshl 57
Ccts 57
St3 57

Classifications:



External Ids:

OMIM 57 191181
UMLS 73 C1860658

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to cervix uteri carcinoma in situ and cervical adenocarcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cell Cycle, Mitotic. The drugs Ropivacaine and Dimethyl fumarate have been mentioned in the context of this disorder. Affiliated tissues include cervix, endothelial and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Description from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 30.9 CDKN2A FHIT TP53
2 cervical adenocarcinoma 29.9 CDKN1A CDKN2A TP53
3 retinoblastoma 29.7 CDKN1A CDKN2A RB1 TP53
4 small cell cancer of the lung 29.7 CDKN2A MYC RB1 TP53
5 papilloma 28.3 CDKN1A CDKN2A PCNA RB1 TP53 UBE3A
6 cervical cancer 25.2 BAX CCNB1 CDKN1A CDKN2A FHIT MYC
7 breast cancer 24.8 BAX BCL2 CCNB1 CDKN1A FHIT MYC
8 lung cancer 24.2 BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT
9 cataract 40 11.2
10 cataract, total congenital 10.9
11 cervical adenosquamous carcinoma 10.9
12 cervicitis 10.9
13 high-grade neuroendocrine carcinoma of the cervix uteri 10.8
14 vulvar adenocarcinoma 10.8 RB1 TP53
15 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
16 keratinizing squamous cell carcinoma 10.7 CDKN2A TP53
17 spitz nevus 10.7 CDKN2A TP53
18 actinic cheilitis 10.7 CDKN1A TP53
19 gallbladder adenoma 10.7 CDKN2A RB1
20 bladder carcinoma in situ 10.7 CDKN2A TP53
21 hepatic angiomyolipoma 10.7 MYC RB1
22 bartholin's gland benign neoplasm 10.6 CDKN2A TP53
23 vulva squamous cell carcinoma 10.6 CDKN2A TP53
24 invasive bladder transitional cell carcinoma 10.6 CDKN1A TP53
25 bladder transitional cell papilloma 10.6 CDKN1A TP53
26 atypical follicular adenoma 10.6 CDKN1A TP53
27 nasal cavity adenocarcinoma 10.6 CDKN2A TP53
28 bone squamous cell carcinoma 10.6 CDKN2A TP53
29 scrotal carcinoma 10.6 CDKN2A TP53
30 anal squamous cell carcinoma 10.6 CDKN2A TP53
31 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 BCL2 MYC
32 diffuse large b-cell lymphoma of the central nervous system 10.5 BCL2 MYC
33 glycogen-rich clear cell breast carcinoma 10.5 CDKN2A TP53
34 b cell prolymphocytic leukemia 10.5 MYC TP53
35 gastric adenosquamous carcinoma 10.5 CDKN2A TP53
36 barrett's adenocarcinoma 10.5 CDKN2A FHIT TP53
37 dedifferentiated liposarcoma 10.5 CDKN2A RB1 TP53
38 cervix carcinoma 10.5 CDKN2A FHIT TP53
39 bizarre leiomyoma 10.4 CDKN2A PCNA
40 cervical carcinosarcoma 10.4 BCL2 TP53
41 malignant mesenchymoma 10.4 CDKN1A FHIT TP53
42 larynx cancer 10.4 CDKN2A FHIT TP53
43 bladder urothelial carcinoma 10.4 FHIT RB1 TP53
44 periosteal chondrosarcoma 10.4 CDKN2A RB1
45 female reproductive organ cancer 10.4 CDKN2A MYC TP53
46 tongue cancer 10.4 CDKN1A CDKN2A TP53
47 respiratory system cancer 10.4 CDKN2A MYC TP53
48 cell type cancer 10.3 CDKN2A MYC TP53
49 anogenital venereal wart 10.3 CDKN2A TP53 UBE3A
50 barrett esophagus 10.3 CDKN2A FHIT TP53

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.63 RB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.63 BCL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.63 CDKN1A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.63 CCNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.63 BCL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.63 CCNB1 RB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.63 BCL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.63 RB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.63 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.63 UBE3A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.63 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.63 BCL2 RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.63 CCNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.63 CCNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.63 BCL2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.63 CCNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.63 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.63 UBE3A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.63 BCL2 CCNB1 RB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.63 CDKN1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.63 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.63 CDKN1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.63 UBE3A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.63 CCNB1 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.63 CDKN1A CCNB1 RB1 UBE3A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.63 RB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.63 BCL2 UBE3A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.63 CDKN1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.63 BCL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.63 BCL2 CDKN1A
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.63 CCNB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.63 BCL2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 CDKN1A CDKN2A BAX BCL2 RB1 TP53
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 CDKN1A CDKN2A BAX BCL2 RB1 MYC
35 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BCL2 CDKN1A CCNB1 BAX TP53 PCNA

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 PCNA TP53 RB1 MYC UBE3A BCL2
2 hematopoietic system MP:0005397 10.18 TAP1 PCNA TP53 FHIT RB1 MYC
3 growth/size/body region MP:0005378 10.16 RB1 MYC PCNA UBE3A TP53 CDKN1A
4 immune system MP:0005387 10.16 MYC TAP1 PCNA FHIT RB1 TP53
5 behavior/neurological MP:0005386 10.15 RB1 MYC UBE3A TP53 BAX CDKN1A
6 mortality/aging MP:0010768 10.14 MYC TAP1 PCNA FHIT RB1 UBE3A
7 integument MP:0010771 10.09 TAP1 TP53 FHIT RB1 MYC UBE3A
8 digestive/alimentary MP:0005381 10.08 RB1 MYC FHIT TP53 BCL2 CDKN2A
9 adipose tissue MP:0005375 10.03 RB1 MYC PCNA TP53 BCL2 CDKN1A
10 hearing/vestibular/ear MP:0005377 9.97 MYC RB1 TP53 BCL2 CDKN1A BAX
11 neoplasm MP:0002006 9.97 TAP1 TP53 RB1 MYC BCL2 CDKN2A
12 muscle MP:0005369 9.91 RB1 MYC TP53 BCL2 CDKN2A BAX
13 nervous system MP:0003631 9.91 RB1 MYC TAP1 UBE3A TP53 CDKN1A
14 no phenotypic analysis MP:0003012 9.7 MYC PCNA RB1 UBE3A TP53 CDKN2A
15 pigmentation MP:0001186 9.35 RB1 MYC TP53 BCL2 CDKN2A
16 reproductive system MP:0005389 9.28 PCNA TP53 RB1 MYC UBE3A BCL2

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
3 Dermatologic Agents Phase 4,Phase 2
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
5 Antibodies Phase 4,Phase 2
6 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
7 Immunoglobulins Phase 4,Phase 2
8 Vaccines Phase 4
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
13 Protective Agents Phase 3,Phase 2
14 Micronutrients Phase 2, Phase 3,Phase 3
15 Trace Elements Phase 2, Phase 3,Phase 3
16 Adjuvants, Immunologic Phase 3
17 Anthelmintics Phase 3
18 Antidotes Phase 3
19 Anti-Infective Agents Phase 3,Phase 2
20 Antimetabolites Phase 3,Phase 2
21 Antimetabolites, Antineoplastic Phase 3,Phase 2
22 Antiparasitic Agents Phase 3
23 Antirheumatic Agents Phase 3,Phase 2
24 Calcium, Dietary Phase 3
25 Vitamin B Complex Phase 3,Phase 2
26 Vitamins Phase 3
27 Folate Nutraceutical Phase 3,Phase 2
28 Vitamin B9 Nutraceutical Phase 3,Phase 2
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
32
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
33
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
34
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
35
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
36
Acetaminophen Approved Phase 2 103-90-2 1983
37
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
38
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
39
Infliximab Approved Phase 2 170277-31-3
40
Loratadine Approved, Investigational Phase 2 79794-75-5 3957
41
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
42
Mycophenolic acid Approved Phase 2 24280-93-1 446541
43
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
44
Promethazine Approved, Investigational Phase 2 60-87-7 4927
45
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
46
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
47
Everolimus Approved Phase 2 159351-69-6 6442177
48
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Pre-emptive Sciatic Bloc to Prevent Lower Limb Phantom Pain Completed NCT00528463 Phase 4
2 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
3 Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels Recruiting NCT02637583 Phase 4 PCV13;PPV23
4 Community-based Follow-up of Severely Malnourished Children Completed NCT01157741 Phase 2, Phase 3
5 CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study Completed NCT01948856 Phase 3 J022X ST;Placebo
6 SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed Completed NCT00002551 Phase 3 fluorouracil;leucovorin calcium;levamisole hydrochloride
7 A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
8 Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy Completed NCT01286402 Phase 2 Bupropion SR
9 GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Completed NCT00068588 Phase 2 capecitabine
10 Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Completed NCT01578668 Phase 2 erlotinib;pemetrexed;cisplatin;erlotinib
11 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients Recruiting NCT02495077 Phase 2 Methylprednisolone;Mycophenolate Mofetil;Tacrolimus;Acetaminophen;Loratadine;Prednisone;Diphenhydramine
12 Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Active, not recruiting NCT00305682 Phase 2 cyclophosphamide;Fludarabine;mycophenolate mofetil;Sirolimus
13 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B Not yet recruiting NCT03519360 Phase 2
14 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A Not yet recruiting NCT03519347 Phase 2
15 Ph I SU011248 + Irinotecan in Treatment of Pts w MG Completed NCT00611728 Phase 1 SU011248 & Irinotecan
16 ECALMIST Versus InSurE in Preterm Infant < 32 Weeks,Multicenter, Multinational RCT Unknown status NCT01848262 Not Applicable
17 Role of Cord Blood Hormones and Epinephrine in the Development of Transient Tachypnea of the Newborn Completed NCT01149928
18 Baby Observational and Nutritional Study Completed NCT01424696
19 Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow Completed NCT01544712 Not Applicable
20 Effects of Carotid Stent Design on Cerebral Embolization Completed NCT00830232 Not Applicable
21 Reproducibility Study of Transcranial Doppler Completed NCT03050567
22 Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors Completed NCT00872677
23 Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED Recruiting NCT03188861
24 Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach Recruiting NCT03089463
25 Blood Markers of Early Pancreas Cancer Not yet recruiting NCT03568630

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

41
Cervix, Endothelial, Lymph Node, Lung, Bone Marrow, Kidney, Pancreas

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 745)
# Title Authors Year
1
Zinc induces apoptosis on cervical carcinoma cells by p53-dependent and -independent pathway. ( 27998772 )
2017
2
The association between RARI^ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis. ( 28639889 )
2017
3
MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4. ( 28577497 )
2017
4
The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma. ( 28627709 )
2017
5
High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration inA vitro. ( 28000879 )
2017
6
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. ( 28623908 )
2017
7
Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma. ( 27909716 )
2017
8
MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene. ( 28385388 )
2017
9
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress. ( 28968467 )
2017
10
Efficacy and safety of argon plasma coagulation in the management of extensive chronic radiation proctitis after pelvic radiotherapy for cervical carcinoma. ( 28707144 )
2017
11
Up-regulation of Transcription Factor 3 Is Correlated With Poor Prognosis in Cervical Carcinoma. ( 28604457 )
2017
12
Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation. ( 28100775 )
2017
13
The eIF3a Arg803Lys genetic polymorphism is associated with susceptibility to and chemoradiotherapy efficacy in cervical carcinoma. ( 28359406 )
2017
14
DJ-1 Expression in Cervical Carcinoma and its Effects on Cell Viability and Apoptosis. ( 27544688 )
2016
15
MicroRNA-200b suppresses cell invasion and metastasis by inhibiting the epithelial-mesenchymal transition in cervical carcinoma. ( 26935156 )
2016
16
The Tumor-promoting Effects of FAM92A1-289 in Cervical Carcinoma Cells. ( 27798880 )
2016
17
Survivin Overexpression Is Associated with Aggressive Clinicopathological Features in Cervical Carcinoma: A Meta-Analysis. ( 27764228 )
2016
18
Identification of genetic variants in TNF receptor 2 which are associated with the development of cervical carcinoma. ( 27145290 )
2016
19
Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody. ( 27220396 )
2016
20
Proteomics-based identification of VDAC1 as a tumor promoter in cervical carcinoma. ( 27419626 )
2016
21
WNT2 Promotes Cervical Carcinoma Metastasis and Induction of Epithelial-Mesenchymal Transition. ( 27513465 )
2016
22
MicroRNA-106b is involved in transforming growth factor I^1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma. ( 26769181 )
2016
23
Rare subtype(s) and frequency of multi-viral subtype high-risk human papilloma virus infection in high-grade squamous intraepithelial lesion and squamous cell carcinoma in a cervical carcinoma prevalent developing country: a multiplex real-time polymerase chain reaction-based pilot study. ( 27659129 )
2016
24
EZH2-mediated repression of GSK-3I^ and TP53 promotes Wnt/I^-catenin signaling-dependent cell expansion in cervical carcinoma. ( 27092879 )
2016
25
MicroRNA-124 inhibits proliferation, invasion, migration and epithelial-mesenchymal transition of cervical carcinoma cells by targeting astrocyte-elevated gene-1. ( 27571703 )
2016
26
A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma. ( 27557505 )
2016
27
Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. ( 27261574 )
2016
28
Oxysterol-binding protein-related protein 4L promotes cell proliferation by sustaining intracellular Ca2+ homeostasis in cervical carcinoma cell lines. ( 27588468 )
2016
29
Proteomic Analysis Revealed the Important Role of Vimentin in Human Cervical Carcinoma HeLa Cells Treated With Gambogic Acid. ( 26499837 )
2016
30
Overexpression of the BRIP1 ameliorates chemosensitivity to cisplatin by inhibiting Rac1 GTPase activity in cervical carcinoma HeLa cells. ( 26680099 )
2016
31
Expression of P21-activated kinase 1 and cell division control protein 42 homolog correlates with clinicopathological features and prognosis in cervical carcinoma. ( 27060895 )
2016
32
CYP1A1 MspI Polymorphism and Cervical Carcinoma Risk in the Multi-Ethnic Population of Malaysia: a Case-Control Study. ( 26838255 )
2016
33
Time to viral clearance after successful conservative treatment for high-risk HPV-infected high-grade cervical intraepithelial neoplasia and early invasive squamous cervical carcinoma. ( 27601381 )
2016
34
MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. ( 26766902 )
2016
35
Malignant mixed mA1llerian tumor mimicking cervical carcinoma. ( 27534864 )
2016
36
Molecular backgrounds of ERAP1 downregulation in cervical carcinoma. ( 26146606 )
2015
37
Study on the correlation between the expression of Ki67 and FasL and prognosis of cervical carcinoma. ( 26345794 )
2015
38
Association between the XRCC1 Arg399Gln polymorphism and risk of cervical carcinoma: a meta-analysis. ( 26345915 )
2015
39
Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma. ( 25412954 )
2015
40
SOX18 Is a Novel Target Gene of Hedgehog Signaling in Cervical Carcinoma Cell Lines. ( 26588701 )
2015
41
High expression of flotillin-2 is associated with poor clinical survival in cervical carcinoma. ( 25755754 )
2015
42
Expression of HNF-1I^ in cervical carcinomas: an immunohistochemical study of 155 cases. ( 25884453 )
2015
43
Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells. ( 26222679 )
2015
44
Lgr5 is a potential prognostic marker in patients with cervical carcinoma. ( 25973068 )
2015
45
A molecular understanding of D-homoestrone-induced G2/M cell cycle arrest in HeLa human cervical carcinoma cells. ( 26228523 )
2015
46
The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. ( 25502079 )
2015
47
Inactivation of PTCH1 is associated with the development of cervical carcinoma: clinical and prognostic implication. ( 25330948 )
2015
48
Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces Ga88/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells. ( 25812484 )
2015
49
Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation. ( 26344356 )
2015
50
Human papilloma virus early proteins E6 (HPV16/18-E6) and the cell cycle marker P16 (INK4a) are useful prognostic markers in uterine cervical carcinomas in Qassim Region--Saudi Arabia. ( 24925218 )
2015

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 BCL2 CCNB1 CDKN1A CDKN2A MYC RB1
2
Show member pathways
13.43 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
3
Show member pathways
13.03 BAX BCL2 CDKN1A MYC RB1 TP53
4
Show member pathways
12.99 BAX CCNB1 CDKN1A CDKN2A PCNA TP53
5 12.9 BAX BCL2 CDKN1A CDKN2A MYC RB1
6
Show member pathways
12.87 BAX BCL2 CDKN1A CDKN2A MYC PCNA
7
Show member pathways
12.86 BAX BCL2 CDKN1A CDKN2A MYC TP53
8
Show member pathways
12.84 BAX BCL2 RB1 TP53
9
Show member pathways
12.82 BAX BCL2 CDKN1A CDKN2A FHIT RB1
10
Show member pathways
12.82 BAX BCL2 CDKN1A CDKN2A MYC RB1
11
Show member pathways
12.69 BAX BCL2 CCNB1 CDKN1A MYC PCNA
12
Show member pathways
12.63 BAX BCL2 CDKN1A MYC TP53
13
Show member pathways
12.61 BAX BCL2 CDKN1A MYC PCNA RB1
14
Show member pathways
12.6 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
15 12.59 CCNB1 CDKN1A CDKN2A PCNA RB1 TP53
16 12.56 BCL2 CDKN1A CDKN2A MYC TP53
17 12.46 BAX CDKN1A CDKN2A MYC PCNA RB1
18
Show member pathways
12.42 CCNB1 CDKN1A CDKN2A RB1 TP53
19 12.38 BAX CDKN1A CDKN2A RB1 TP53 UBE3A
20 12.36 BCL2 CDKN1A MYC RB1 TP53
21 12.34 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
22
Show member pathways
12.33 BAX BCL2 CDKN1A RB1 TP53
23 12.29 BAX CDKN1A MYC TP53
24
Show member pathways
12.29 BAX BCL2 CCNB1 CDKN1A CDKN2A MYC
25
Show member pathways
12.26 CDKN1A CDKN2A MYC RB1
26 12.24 BAX BCL2 MYC RB1 TP53
27 12.24 CCNB1 CDKN1A CDKN2A MYC RB1 TP53
28 12.23 BAX CDKN1A MYC TP53
29 12.22 BAX BCL2 CDKN1A MYC TP53
30
Show member pathways
12.19 BAX BCL2 RB1
31
Show member pathways
12.14 BAX CDKN1A MYC PCNA TP53
32 12.13 BCL2 CDKN1A CDKN2A RB1 TP53 UBE3A
33
Show member pathways
12.11 BAX MYC TP53
34
Show member pathways
12.11 BAX CDKN1A TP53
35 12.07 CDKN1A CDKN2A MYC RB1 TP53
36
Show member pathways
12.06 BAX BCL2 CDKN1A MYC
37 12.05 CDKN1A MYC TP53
38 12.05 BCL2 CDKN1A MYC TP53
39
Show member pathways
12.03 CCNB1 MYC PCNA RB1 TP53
40 12.03 BAX BCL2 CDKN1A CDKN2A MYC TP53
41
Show member pathways
12.02 BAX CCNB1 CDKN1A PCNA TP53
42
Show member pathways
12.01 BAX BCL2 TP53
43 12 MYC RB1 TP53
44 11.99 BAX BCL2 TP53
45
Show member pathways
11.97 BAX BCL2 TP53
46 11.96 BCL2 CDKN1A CDKN2A PCNA RB1 TP53
47 11.89 BAX CCNB1 MYC TP53
48 11.87 CDKN1A RB1 UBE3A
49 11.86 BCL2 CCNB1 CDKN1A MYC
50
Show member pathways
11.85 CCNB1 CDKN1A TP53

GO Terms for Suppressor of Tumorigenicity 3

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.92 BCL2 CCNB1 CDKN1A CDKN2A MYC PCNA
2 mitochondrion GO:0005739 9.5 BAX BCL2 CDKN2A FHIT MYC TAP1
3 replication fork GO:0005657 9.37 PCNA TP53
4 pore complex GO:0046930 9.16 BAX BCL2
5 PCNA-p21 complex GO:0070557 8.62 CDKN1A PCNA
6 nucleus GO:0005634 10 BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.97 BCL2 CDKN1A MYC TP53
2 response to drug GO:0042493 9.97 BCL2 CCNB1 CDKN1A MYC
3 negative regulation of gene expression GO:0010629 9.95 CCNB1 CDKN1A MYC RB1
4 cellular response to DNA damage stimulus GO:0006974 9.95 BAX BCL2 CDKN1A MYC PCNA TP53
5 negative regulation of cell proliferation GO:0008285 9.91 BAX BCL2 CDKN1A CDKN2A RB1 TP53
6 negative regulation of cell growth GO:0030308 9.85 BCL2 CDKN1A CDKN2A TP53
7 regulation of mitotic cell cycle GO:0007346 9.84 CDKN1A MYC RB1
8 cellular response to hypoxia GO:0071456 9.84 BCL2 CCNB1 MYC TP53
9 response to toxic substance GO:0009636 9.83 BAX BCL2 CCNB1 CDKN1A
10 positive regulation of fibroblast proliferation GO:0048146 9.81 CCNB1 CDKN1A MYC
11 G1/S transition of mitotic cell cycle GO:0000082 9.81 CDKN1A CDKN2A MYC RB1
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.8 BCL2 CDKN1A RB1
13 neuron apoptotic process GO:0051402 9.79 BAX BCL2 RB1
14 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.78 BAX FHIT TP53
15 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.77 BAX BCL2 TP53
16 negative regulation of fibroblast proliferation GO:0048147 9.76 BAX MYC TP53
17 Ras protein signal transduction GO:0007265 9.76 CDKN1A CDKN2A RB1 TP53
18 intrinsic apoptotic signaling pathway GO:0097193 9.73 BAX CDKN1A TP53
19 cell cycle arrest GO:0007050 9.72 CDKN1A CDKN2A MYC RB1 TP53
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.71 CDKN1A CDKN2A
21 response to X-ray GO:0010165 9.7 CDKN1A TP53
22 release of cytochrome c from mitochondria GO:0001836 9.7 BAX BCL2
23 cellular senescence GO:0090398 9.7 CDKN1A CDKN2A
24 negative regulation of apoptotic signaling pathway GO:2001234 9.7 BAX BCL2
25 B cell homeostasis GO:0001782 9.69 BAX BCL2
26 positive regulation of smooth muscle cell migration GO:0014911 9.69 BCL2 MYC
27 negative regulation of phosphorylation GO:0042326 9.69 CDKN1A CDKN2A
28 positive regulation of protein oligomerization GO:0032461 9.68 BAX TP53
29 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.68 CDKN1A TP53
30 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.68 BAX BCL2
31 hypothalamus development GO:0021854 9.68 BAX MYC
32 regulation of mitochondrial membrane permeability GO:0046902 9.67 BCL2 TP53
33 apoptotic mitochondrial changes GO:0008637 9.67 BAX BCL2 CDKN2A
34 cellular response to UV GO:0034644 9.67 BAX MYC PCNA TP53
35 regulation of protein heterodimerization activity GO:0043497 9.65 BAX BCL2
36 regulation of protein homodimerization activity GO:0043496 9.65 BAX BCL2
37 regulation of cell cycle GO:0051726 9.65 BAX BCL2 CCNB1 CDKN1A RB1
38 leukocyte homeostasis GO:0001776 9.64 BAX BCL2
39 signal transduction by p53 class mediator GO:0072331 9.64 CDKN1A TP53
40 regulation of nitrogen utilization GO:0006808 9.58 BAX BCL2
41 replicative senescence GO:0090399 9.58 CDKN1A CDKN2A TP53
42 positive regulation of developmental pigmentation GO:0048087 9.57 BAX BCL2
43 ovarian follicle development GO:0001541 9.46 BAX BCL2 MYC UBE3A
44 response to gamma radiation GO:0010332 9.26 BAX BCL2 MYC TP53
45 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.02 BAX CCNB1 CDKN1A PCNA TP53
46 apoptotic process GO:0006915 10.07 BAX BCL2 CDKN2A FHIT RB1 TP53
47 cell cycle GO:0007049 10.06 CCNB1 CDKN1A CDKN2A RB1 TP53
48 viral process GO:0016032 10.02 BAX RB1 TAP1 TP53 UBE3A
49 cell proliferation GO:0008283 10.02 BAX BCL2 MYC PCNA TP53

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 BAX BCL2 FHIT PCNA RB1 TP53
2 protein kinase binding GO:0019901 9.71 CCNB1 CDKN1A CDKN2A TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN1A CDKN2A
4 transcription factor binding GO:0008134 9.35 BCL2 CDKN2A MYC RB1 TP53
5 disordered domain specific binding GO:0097718 9.33 CDKN2A RB1 TP53
6 BH3 domain binding GO:0051434 9.26 BAX BCL2
7 ubiquitin protein ligase binding GO:0031625 9.02 BCL2 CDKN1A FHIT RB1 TP53

Sources for Suppressor of Tumorigenicity 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....